Literature DB >> 1365869

Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers.

K H Simpson1, P Murphy, P V Colthup, P Whelan.   

Abstract

This study measured the concentrations of ondansetron in plasma and cerebrospinal fluid (CSF) in six volunteers after oral dosing to steady state. Ondansetron concentrations ranged from 39.5-147 ng ml-1 in plasma and from 2.6-15.4 ng ml-1 in CSF. There was good correlation between plasma and CSF concentrations (r = 0.89, p = 0.017). CSF concentrations were less than 15% of plasma concentrations in all cases, indicating that the rate of penetration of the blood brain barrier by ondansetron is low.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365869     DOI: 10.1007/bf02247730

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  3 in total

1.  The determination in plasma and pharmacokinetics of ondansetron.

Authors:  P V Colthup; J L Palmer
Journal:  Eur J Cancer Clin Oncol       Date:  1989

2.  A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

Authors:  J Hainsworth; W Harvey; K Pendergrass; B Kasimis; D Oblon; G Monaghan; D Gandara; P Hesketh; A Khojasteh; G Harker
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

3.  Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly.

Authors:  P V Colthup; C C Felgate; J L Palmer; N L Scully
Journal:  J Pharm Sci       Date:  1991-09       Impact factor: 3.534

  3 in total
  12 in total

1.  Ondansetron reverses antihypersensitivity from clonidine in rats after peripheral nerve injury: role of γ-aminobutyric acid in α2-adrenoceptor and 5-HT3 serotonin receptor analgesia.

Authors:  Ken-ichiro Hayashida; Masafumi Kimura; Masaru Yoshizumi; Shotaro Hobo; Hideaki Obata; James C Eisenach
Journal:  Anesthesiology       Date:  2012-08       Impact factor: 7.892

2.  A Flawed Design Produces Flawed Results.

Authors:  Gary Peltz
Journal:  J Addict Med       Date:  2018 May/Jun       Impact factor: 3.702

3.  5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 4.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

5.  The physiological control of eating: signals, neurons, and networks.

Authors:  Alan G Watts; Scott E Kanoski; Graciela Sanchez-Watts; Wolfgang Langhans
Journal:  Physiol Rev       Date:  2021-09-06       Impact factor: 37.312

Review 6.  Ondansetron clinical pharmacokinetics.

Authors:  F Roila; A Del Favero
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

Review 7.  De-stabilization of the positive vago-vagal reflex in bulimia nervosa.

Authors:  Patricia L Faris; Randall D Hofbauer; Randall Daughters; Erin Vandenlangenberg; Laureen Iversen; Robert L Goodale; Robert Maxwell; Elke D Eckert; Boyd K Hartman
Journal:  Physiol Behav       Date:  2007-11-28

8.  Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Neda Askari; Mahdieh Moin; Mohammad Sanati; Masih Tajdini; Seyed-Mohammad-Reza Hosseini; Amirhossein Modabbernia; Babak Najand; Samrand Salimi; Mina Tabrizi; Mandana Ashrafi; Reza Hajiaghaee; Shahin Akhondzadeh
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 6.497

9.  Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n).

Authors:  R Mahesh; S Bhatt; T Devadoss; Ak Jindal; Bk Gautam; Dk Pandey
Journal:  J Young Pharm       Date:  2012-10

10.  A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy.

Authors:  Hee Yeon Lee; Hoon-Kyo Kim; Kyung Hee Lee; Bong-Seog Kim; Hong Suk Song; Sung Hyun Yang; Joon Hee Kim; Yeul Hong Kim; Jong Gwang Kim; Sang-We Kim; Dong-Wan Kim; Si-Young Kim; Hee Sook Park
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.